Explore the science behind AntiClastic™ cyclic oligonucleotide design.

Poster Overview:

This poster highlights a novel approach to antisense architecture using transient cyclic structures designed to improve potency, reduce immune activation, and enhance the overall drug-like properties of RNA therapeutics. Download the poster to see how cyclic design can help overcome limitations of traditional linear ASOs.

In this poster, you’ll See:
  • The design rationale behind AntiClastic™ cyclic antisense oligonucleotides
  • How 3’-3’ and 5’-5’ cyclic linkages influence biological performance
  • Data demonstrating improved potency compared to conventional gapmers
  • Evidence of reduced immune activation and improved safety profile

Complete this form to download and view the poster

Discover more about Genetic Medicines at Alloy

Shaping the RNA Century
  • Improved Potency: The AntiClastic cyclic and 5’ end-engineering results in up to a 50-fold improvement in in vitro potency.
  • Increased Patient Safety: Reduced engagement of off-target RNA and pattern recognition receptors mitigates the inflammatory response, thereby improving the therapeutic index.
  • IP Protection: The AntiClastic platform creates novel, globally IP-protected therapeutic structures.
  • Clinically Validated Methods: Manufactured using conventional chemical methods and engineered with building blocks of clinically validated and established oligonucleotide therapeutic modifications.